Developments in serologic detection of human pancreatic adenocarcinoma

Scandinavian Journal of Gastroenterology

Volumn 34, Issue 9, 1999, Pages 833-844

  Eskelinen, Matti ^a   Haglund, Ulf ^b  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CA 19-9 ANTIGEN; CA 195 ANTIGEN; CA 242 ANTIGEN; CA 494 ANTIGEN; CA 50 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN; ELASTASE; GLYCOPROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CAM 17 1; MUCIN; TISSUE POLYPEPTIDE ANTIGEN; TRYPSIN INHIBITOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ANTIGEN DETECTION; CANCER DIAGNOSIS; DIAGNOSTIC ACCURACY; GENE MUTATION; HUMAN; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PANCREAS CARCINOMA; PRIORITY JOURNAL; REVIEW; SERODIAGNOSIS; TUMOR SUPPRESSOR GENE;

EID: 0032888282     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655299750025273     Document Type: Review

References (166)

1. Link KH, Formentini A, Leder G, Fortnagel G, Sartori N, Schatz M, et al. Resection and radiochemotherapy of pancreatic cancer - the future? Langenbecks Arch Surg 1998;383:134-44.
2. Trede M, Schwall S, Saeger H. Survival after pancreaticoduodenectomy. Ann Surg 1990;211:447-58.
3. Warshaw A, Fernandez del Castillo C. Pancreatic carcinoma. N Engl J Med 1990;326:455-65.
4. Watanapa P, Williamson RC. Surgical palliation for the pancreatic cancer: developments during the past two decades. Br J Surg 1992;79:8-20.
5. Janes RH, Niederhuber JE, Chmiel JS, Winchester DP, Ocwieja KC, Karnell LH, et al. National patterns of care for pancreatic cancer. Ann Surg 1996;223:261-72.
6. Cameron JL, Crist D, Sitzmann JV, Hruban RH, Boitnott JK, Seidler AJ, et al. Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg 1991;161:120-4.
7. Yeo CJ, Cameron JL, Lillemoe KD, Sitzmann JV, Hruban RH, Goodman SN, et al. Pancreaticoduodenectomy for the head of the pancreas; 201 patients. Ann Surg 1995;221:721-33.
8. Trede M, Saeger HD, Schwall S, Rumstadt B. Resection of pancreatic cancer- surgical achievements. Langenbecks Arch Surg 1998;383:121-8.
9. Gudjonsson B. Cancer of the pancreas. 50 years of surgery. Cancer 1987;60:2284-303.
10. Roulston JE. Novel tumour markers: a diagnostic role in pancreatic cancer? [editorial]. Br J Cancer 1994;70:389-90.
11. Tada M, Omata M, Kawai S, Saisho H, Ohio M, Saitu K, et al. Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma. Cancer Res 1993;53:2472-4.
12. Laurent-Puig P, Lubin R, Semhoun-Ducloux S, Pelletier G, Fourre C, Ducreux M, et al. Antibodies against p53 protein in serum of patients with benign or malignant biliary diseases. Gut 1995;36:455-8.
13. Mulcahy HE, Lyautey J, Lederrey C, Chen X, Anker P, Alstead KM, et al. A prospective study of K-ras mutations in the plasma of pancreatic cancer patients. Clin Cancer Res 1998;4:271-5.
14. Gold P, Freedman S. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 1965;121:439-62.
15. Hammarström S, Shively J, Paxton R, Beatly B, Larsson A, Gosh R et al. Cancer Res 1989;49:4852-8.
16. Nap M, Mollgard K, Burtin P, Fleuren GJ. Immunohistochemistry of carcinoembryonic antigen in the embryo, fetus and adult. Tumor Biol 1988;9:145-53.
17. Alexander J, Silverman N, Chretien P. Effect of age and cigarette smoking on carcinoembryonic antigen levels. JAMA 1976;235:1975-9.
18. Begeni RHJ. The value of carcinoembryonic antigen measurement in clinical practice. Ann Clin Biochem 1984;21:231-8.
19. Loewenstein MS, Zamcheck N. Carcinoembryonic antigen (CEA) levels in benign gastrointestinal disease states. Cancer 1978;42:1412-8.
20. O'Brien MJ, Bronstein B, Zamchech N, Saravis C, Burke B, Gottlieb LS. Cholestasis and hepatic metastases: a factor contributing to the extreme elevations of carcinoembryonic antigen. J Natl Cancer Inst 1980;64: 1291-4.
21. Hayes DF, Zurawski VR Jr, Kufe DW. Comparison of circulating CA 15-3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol 1986;4:1542-50.
22. Eskelinen M, Metsä-Ketelä T, Collan Y, Valkamo F. Measurement of serum CEA in breast disease: use in the diagnostic and therapeutic protocol of breast tumors. J Tumor Marker Oncol 1988;3:399-405.
23. Eskelinen M, Kataja V, Hämäläinen E, Kosma V-M, Penttilä I, Alhava E. Serum tumour markers CEA, AFP, CA 15-3, TPS and Neu in diagnosis of breast cancer. Anticancer Res 1997;17:1231-4.
24. Pasanen P, Eskelinen M, Partanen K, Pikkarainen P, Penttilä I, Alhava B. A prospective study of serum tumour markers CEA, CA 50, CA 242, TPA and TPS in the diagnosis of pancreatic carcinoma with special reference to multivariate diagnostic score. Br J Cancer 1994;69:562-5.
25. Eskelinen M, Pasanen P, Kulju A, Janatuinen E, Miettinen P, Poikolainen E, et al. Clinical evaluation of serum tumour markers CEA, CA 50 and CA 242 in colorectal cancer. Anticancer Res 1994;14:1427-32.
26. Audisio RA, Veronesi P, Maisonneuve P, Chiappa A, Andreoni B, Bomberdieri E, et al. Clinical relevance of serological markers in the detection and follow-up of pancreatic adenocarcinoma. Surg Oncol 1996;5:49-63.
27. Banwo O, Versey J, Hobbs JR. New oncofetal antigen for human pancreas. Lancet 1974;Volume no.?:643-5.
28. Gelder FB, Reese CJ, Moossa AR, Hall T, Hunter R. Purification, partial characterization and clinical evaluation of a pancreatic oncofetal antigen. Cancer Res 1978;38:313-24.
29. Mihas AA. Immunologic studies on a pancreatic oncofetal protein. J Natl Cancer Inst 1978;60:1439-44.
30. Nishida K, Sugiura M, Yoshikawa T, Kondo M. Enzyme immunoassay of pancreatic oncofetal antigen (POA) as a marker of pancreatic cancer. Gut 1985;26:450-5.
31. Schmiegel WH, Eberl W, Kreiker C, Kalthoff H, Butzow GH, Jessen K, et al. Multiparameter tumor marker (CA 19-9, CEA, AFP, POA)) analyses of pancreatic juices and sera in pancreatic diseases. Hepatogastroenterology 1985;32:141-5.
32. Björklund B, Björklund V. Antigenity of pooled human malignant and normal tissues by cyto-immunological technique: presence of an insoluble, heatlabile tumor antigen. Int Arch Allergy 1957;10:153-84.
33. Björklund B. On the nature and clinical use of tissue polypeptide antigen (TPA). Tumor Diagn 1980;1:9-20.
34. Andriulli A, Gindro T, Piantino P, Massero G, Cavallini G, Farini R, et al. Efficacy of CA 19-9, TPA and CEA assays in pancreatic cancer [abstract]. Digestion 1983;28:9-10.
35. Panucci A, Fabris C, Del Favero G, Basso D, Marchioro L, Piccoli A. Tissue polypeptide antigen (TPA) in pancreatic cancer diagnosis. Br J Cancer 1985;52: 801-3.
36. Meduri F, Doni MG, Merenda R, Bizzarini M, Neri D, Gerunda GE, et al. The rule of the leukocyte adherence inhibition (LAI), CA 19-9, and tissue polypeptide antigen (TPA) tests in the diagnosis of pancreatic cancer. Cancer 1989:64:1103-6.
37. Benini L, Cavallini G, Zordan D, Rizzotti P, Rigo L, Brocco G, et al. A clinical evaluation of monoclonal (CA 19-9, CA 50, CA 12-5) and polyclonal (CEA, TPA) antibody-defined antigens for the diagnosis of pancreatic cancer. Pancreas 1988;3:61-6.
38. Pasanen P, Eskelinen M, Pikkarainen P, Partanen K, Penttilä I. Clinical evaluation of tissue polypeptide antigen (TPA) in the diagnosis of pancreatic carcinoma. Anticancer Res 1993;13: 1883-8.
39. Saito S, Taguchi K, Nishimura N, Watanabe A, Ogashi K, Niwa M, et al. Clinical usefulness of computer-assissted diagnosis using combination assay of tumour markers for pancreatic cancer. Cancer 1993;72:381-8.
40. Eskelinen M, Hippeläinen M, Salmela E, Paajanen H, Alhava E, Syrjänen K. A prospective study of tissue polypeptide specific antigen (TPS) in breast cancer diagnosis. Anticancer Res 1992:12:2033-6.
41. Banfi G, Zerbi A, Pastori S, Parolini D, Di Carlo V, Bonini P. Behavior of tumor markers CA 19-9, CA 195, CAM 43, CA 242 and TPS in the diagnosis and follow-up of pancreatic cancer. Clin Chem 1993;39:420-3.
42. Pasanen P, Eskelinen M, Partanen K, Pikkarainen P, Penttilä I, Alhava E. Diagnostic value of tissue polypeptide specific antigen in patients with pancreatic carcinoma. Tumor Biol 1994;15:52-60.
43. Stenman U-H, Huhtala M-L, Koistinen R, Seppälä M. Immunochemical demonstration of an ovarian cancer associated urinary peptide. Int J Cancer 1982;30:53-7.
44. Huhtala M-L, Pesonen K, Kalkkinen N, Stenman U-H. Purification and characterization of a tumor-associated trypsin inhibitor from the urine of a patient with ovarian cancer. J Biol Chem 1982;257:13713-6.
45. Haglund C, Huhtala M-L, Halila H, Nordling S, Roberts P, Scheinin TM, et al. Tumour-associated trypsin inhibitor, TATI, in patients with pancreatic cancer, pancreatitis and benign biliary diseases. Br J Cancer 1986;54:297-303.
46. Taccone W, Mazzoni W, Belli M. Evaluation of TATI and other markers in solid tumors. Scand J Clin Lab Invest 1991;51:25-32.
47. Masson P, Pålsson B, Andren-Sandberg Å. Evaluation of CEA, CA 19-9, CA 195, and TATI with special reference to pancreatic disorders. Int J Pancreatol 1991;8:333-44.
48. Blebani M, Basso D, Fabris C, Meggiato T, Del Favero G, Panozzo MP, et al. Tumor-associated trypsin inhibitor in patients with chronic pancreatic disease. Klin Wochenschr 1989;67:1029-32.
49. Aroasio E, Piantino P. TATI in pancreatic diseases. Scand J Clin Lab Invest 1991;51:71-3.
50. Pasanen P, Eskelinen M, Pikkarainen P, Partanen K, Penttilå I, Alhava E. Tumor-associated trypsin inhibitor in the diagnosis of pancreatic carcinoma. J Cancer Res Clin Oncol 1994;120: 494-7.
51. Lan MS, Finn OJ, Fernsten PD, Metzgar RS. Isolation and properties of a human pancreatic adenocarcinoma-associated antigen DU-PAN 2. Cancer Res 1985;45:305-10.
52. Borowitz MJ, Tuck FL, Sindelar WF, Fernsten PD, Metzgar RS. Monoclonal antibodies against human pancreatic adenocarcinoma: distribution of DU-PAN-2 antigen on glandular epithelia and adenocarcinomas. J Natl Cancer Inst 1984;72: 999-1005.
53. Haviland AE, Borowitz MJ, Killenberg PG, Lan MS, Metzgar RS. Detection of an oncofetal antigen (DU-PAN-2) in sera of patients with non-malignant hepatobiliary diseases and hepatomas. Int J Cancer 1988;41:789-93.
54. Sawabu N, Toya D, Takemori Y, Hattori N, Fukui M. Measurement of pancreatic cancer-associated antigen (DU-PAN-2) detected my monoclonal antibody in sera of patients with digestive cancers. Int J Cancer 1986;37:693-6.
55. Ohshio G, Manabe T, Walanabe Y, Endo K, Kudo H, Suzuki T, et al. Comparative studies of DU-PAN-2. CEA and CA 19-9 in the serum and bile of patients with pancreatic and biliary tract diseases: evaluation of the influence of obstructive jaundice. Am J Gastroenterol 1990;85: 1370-6.
56. Melzgar RS, Rodriguez N, Finn OJ, Lan MS, Daasch VN, Fernsten PD, et al. Detection of a pancreatic cancer-associated antigen (DU-PAN-2 antigen) in serum and aseites of patients with adenocarcinoma. Proc Natl Acad Sci USA 1984;81: 5242-6.
57. Mahvi DM, Meyers WC, Bast RC, Seigler HF, Melzgar RS. Carcinoma of the pancreas. Therapeutic efficacy as defined by a serodiagnostic test utilising a monoclonal antibody. Ann Surg 1985;202:440-5.
58. Takasaki H, Uchida E, Tempera M, Burnett DA, Melzgar RS, Pour P. Correlative study on expression of CA 19-9 and DU-PAN-2 in tumor tissue and in serum of pancreatic cancer patients. Cancer Res 1988;48:1435-8.
59. Kiriyama S, Haykawa T, Kondo T, Shibata T, Kitagawa M, Ono H, et al. Usefulness of a new tumor marker, Span-1, for the diagnosis of pancreatic cancer. Cancer 1990;65:1557-61.
60. Satake K, Takeuchi T. Comparison of CA 19.9 with other tumor markers in the diagnosis of cancer of the pancreas. Pancreas 1994;9:720-4.
61. Kawa S, Tokoo M, Oguchi H, Furuta S, Homma T, Haseqawa Y, et al. Epitope analysis of Span-1 and Dupan-2 using synthesized glycoconjugates siallylact-N-Fucopentaose II and Siallyllact-N-Tetraose. Pancreas 1994;9:692-7.
62. Kawa S, Oguchi H, Kobayashi T, Tokoo M, Furuta S, Kanai M, et al. Elevated serum levels of Dupan-2 in pancreatic cancer patients negative for Lewis blood group phenotype. Br J Cancer 1991;64:899-902.
63. Chung YS, Ho JJL, Kim YS, Tanaka H, Nakata B, Hiura A, et al. The detection of human pancreatic cancer-associated antigen in the serum of cancer patients. Cancer 1987;60: 1636-43.
64. Kobayashi T, Kawa S, Tokoo M, Oguchi H, Kiyosawa K, Furuta S, et al. Comparative study of CA 50, Span-1, and CA 19-9 in the diagnosis of pancreatic cancer. Scand J Gastroenterol 1991;26:787-97.
65. Satake K. Diagnosis of pancreatic cancer. Int J Pancreatol 1991;9:93-8.
66. Ho JJL, Chung Y-S, Ryan W, Henslee JG, Kim YS. Evaluation of factors affecting the performance of enzymatic SPan-1 immunoassays for pancreatic cancer. J Immunol Methods 1989;125:97-104.
67. Ho JJL, Chung Y-S, Yuan M, Henslee JG, Kim YS. Differences in expression of SPan-1 and CA 15-3 antigens in blood and tissues. Int J Cancer 1992;52:693-700.
68. Chung YS, Nakata B, Sawada T, et al. New radioimmunoassay for pancreatic cancer-associated antigen SPan-1 with reference to differential diagnosis and monitoring in pancreatic cancer. Int J Oncol 1993;2:921-6.
69. Satake K, Chung Y-S, Yokomatsu H, Nakata B, Tanaka H, Sawada T, et al. A clinical evaluation of various tumor markers for the diagnosis of pancreatic cancer. Int J Pancreatol 1990;7:25-36.
70. Takeda S, Nakuo A, Ichihara T, Suzuki Y, Nonami T, Harada A, et al. Serum concentration and immunohistochemical localization of SPan-1 antigen in pancreatic cancer. A comparison with CA 19-9 antigen, Hepatogastroenterology 1991:38:143-8.
71. Chung YS, Nakata B, Yokomatsu H, et al. Clinical significance of measurement of new pancreatic cancer associated antigen. Int J Oncol 1993;2:921-926.
72. Ho JJL, Norton KA, Chung Y-S, Kim YS. Expression of CA 19-9, DU-PAN-2 and SPan-1 antigens on two types of normal salivary mucins. Oncol Res 1993;5:347-56.
73. Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Fuhner P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 1979;5:957-71.
74. Magnani J, Steplewski Z, Koprowski H, Ginsburg V. Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. Cancer Res 1983;43:5489-92.
75. Atkinson BF, Ernst CS, Herlyn M, Steplewski Z, Sears HF, Koprowski H. Gastrointestinal cancer-associated antigen in immunoperoxidase assay. Cancer Res 1982;42:4820-3.
76. Dietel M, Arps H, Klapdor R, Muller-Hagen S, Sieck M, Hoffman L. Antigen detection by the monoclonal antibodies CA 19-9 and CA 125 in normal and tumor tissue and patients sera. J Cancer Res Clin Oncol 1986;111:257-65.
77. Haglund C, Lindgren J, Roberts P, Nordling S. Tissue expression of the tumor marker CA 50 in benign and malignant pancreatic lesions. A comparison with CA 19-9. Int J Cancer 1986;38:841-6.
78. Haglund C, Lindgren J, Roberts P, Nordling S. Gastrointestinal cancer-associated antigen CA 19-9 in histological specimes of pancreatic tumours and pancreatitis. Br J Cancer 1986;53:189-95.
79. Nishida K, Miyagawa H, Yoshikawa T, Kondo M. Concentration and localization of carbohydrate antigen 19-9 in tissues of pancreatic cancer. Oncology 1988;45:166-71.
80. Schwenk J, Makowitzky J. Tissue expression of the cancer-associated antigens CA 19-9 and CA-50 in chronic pancreatitis and pancreatic carcinoma. Int J Pancreatol 1989;5:85-98.
81. Wakabayashi T, Sawabu N, Takemori Y, Satomura Y, Kidani H, et al. Diagnostic significance of cancer-associated carbohydrate antigen (CA 19-9) concentrations in pancreatic juice: analysis in pure pancreatic juice collected by endoscopic aspiration and immunohistochemical study in chronic pancreatitis. Pancreas 1993;8:151-9.
82. Herlyn M, Sears HF, Steplewski Z, Koprowski H. Monoclonal antibody detection of a circulating tumor-associated antigen. I. Presence of antigen in sera of patients with colorectal, gastric and pancreatic carcinoma. J Clin Immunol 1982:2:135-40.
83. Del Villano BC, Brennan S, Brock P, Bucher C, Liu V, McClure M, et al. Radioimmunometric assay for a monoclonal antibody-defined tumor marker. Clin Chem 1983;29:549-52.
84. Green PJ, Dallas SK, Westkaemper P, Schwartz HG, Klug TL, Zurawski VR. CA 19-9 and CA 125 levels in the sera of normal blood donors in relation to smoking history. J Natl Cancer Inst 1986;77:337-41.
85. Tatsuta M, Yamamura H, Iishi H, Ichii M, Noguchi S, Yamamoto R, et al. Values of CA 19-9 in the serum, pure pancreatic juice, and aspirated pancreatic material in the diagnosis of malignant pancreatic tumor. Cancer 1985;56: 2669-73.
86. Yoshikawa T, Nishida K, Tanigawa M, Fukumoto K, Kondo M. Carbohydrate antigenic determinant (CA 19-9) and other tumor markers in gastrointestinal malignancies. Digestion 1985;31:67-76.
87. Steinberg WM, Gelfand R, Anderson KK, Glenn J, Kurtzman SH, Sindelar WP, et al. Comparison of the sensitivity and specificity of the CA 19-9 and CEA assays in detecting cancer of the pancreas. Gastroenterology 1986;90:343-9.
88. Pleskow DK, Berger HJ, Gyves J, Allen E, McLean A, Podolsky DK. Evaluation of a serologic marker, CA 19-9, in the diagnosis of pancreatic cancer. Ann Intern Med 1989;110:704-9.
89. Safi F, Röscher R, Beger HG. Tumor markers in pancreatic cancer. Sensitivity and specificity of CA 19-9. Hepatogastroenterology 1989;36:419-23.
90. Piantino P, Andriulli A, Gindro T, Pecchio F, Massero G, Cavallini G, et al. CA 19-9 assay in differential diagnosis of pancreatic carcinoma from inflammatory pancreatic diseases. Am J Gastroenterol 1986;81:436-9.
91. Haglund C, Kuusela P, Jalanko H, Roberts P. Serum CA 50 as a tumour marker in pancreatic cancer: a comparison with CA 19-9. Int J Cancer 1987;39:477-81.
92. Malesci A, Montorsi M, Mariani A, Santambrogio R, Bonato C, Bissi O, et al. Clinical utility of the serum CA 19-9 test for diagnosing pancreatic carcinoma in symptomatic patients: a prospective study. Pancreas 1992;7:497-502.
93. Chang TH, Steplewski Z, Sears HF, Koprowski H. Detection of monoclonal antibody-defined colorectal carcinoma antigen by solid-phase binding inhibition radioimmunoassay. Hybridoma 1981;1:37-45.
94. Koprowski H, Herlyn M, Steplewski Z, Sears HF. Specific antigen in serum of patients with colon carcinoma. Science 1981;212:53-4.
95. Ritts RE Jr. Del Villano BC, Go VLW, Herberman RB, Klug TL, Zurawski VR Jr. Initial clinical evaluation of an immunoradio-metric assay for CA 19-9 using the NCl serum bank. Int J Cancer 1984;33:339-45.
96. Koprowski H, Brockhaus M, Blaszczyk M, Magnani J, Steplewski Z, Ginsburg V. Lewis blood-type may affect the incidence of gastrointestinal cancer. Lancet 1982;1:1332-3.
97. Masson P, Pålsson B, Andren-Sandberg A. Cancer-associated tumour markers CA 19-9 and CA-50 in patients with pancreatic cancer with special reference to the Lewis blood cell status. Br J Cancer 1990;62:118-21.
98. Del Favero G, Fabris C, Plebani M, Panucci A, Piccoli A, Perobelli L, et al. CA 19-9 and CEA in pancreatic cancer diagnosis. Cancer 1986;57:1576-9.
99. Haglund C, Roberts P, Kuusela P, Jalanko H. Tumour markers CA 19-9 and CA 50 in digestive tract malignancies. Scand J Gastroenterol 1992:27:169-74.
100. Barone D, Onetto M, Conio M, Paganuzzi M, Saccomonno S, Aste H, et al. CA 19-9 assay in patients with extrahepatic cholestatic jaundice. Int J Biol Markers 1988;3:95-100.
101. Fabris G, Del Favero G, Basso D, Piccoli A, Meggatio T, Angonese C, et al. Serum markers and clinical data in diagnosing pancreatic cancer: a contrastive approach. Am J Gastroenterol 1988;83:549-53.
102. Harmenberg AE, Wahren B, Wiechel KL. Tumor markers carbohydrate antigen CA 19-9 and CA-50 and CEA in pancreatic cancer and benign diseases of the pancreatobiliary tract. Cancer Res 1988;48:1985-8.
103. Molina LM, Diez M, Cava MT, Maestro ML, Ortega MD, Mendiz JG, et al. Tumor markers in pancreatic cancer: a comparative study between CEA, CA 19-9 and CA 50. Int J Biol Markers 1990;5:127-32.
104. Lucarotti ME, Habib NA, Kelly SB, Rothnie ND, Nelson O, Lindholm L, et al. Clinical evaluation of combined use of CEA, CA 19-9 and CA 50 in the serum of patients with pancreatic carcinoma. Eur J Surg Oncol 1991;17:51-3.
105. Hyöty M, Hyöty H, Aaran RK, Airo I, Nordback I. Tumour antigens CA 195 and CA 19-9 in pancreatic juice and serum for the diagnosis of pancreatic carcinoma. Eur J Surg 1992;158:173-9.
106. Steinberg WM. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 1990;85:350-5.
107. Haglund C, Lundin J, Kuusela P, Roberts P. CA 242- A new tumour marker for pancreatic cancer. A comparison with CA 19-9, CA 50 and CEA. Br J Cancer 1994;70:487-92.
108. Craxi A, Patti C, Aragona E. Serum CA 19-9 levels in patients with hepatocellular carcinoma or cirrhosis. Ital J Gastroenterol 1985;17:288-9.
109. Albert MB, Steinberg WM, Henry JP. Elevated serum levels of tumor marker CA 19-9 in acute cholangitis. Dig Dis Sci 1988;33:1223-5.
110. Haglund C, Roberts P, Kuusela P, Scheinin TM, Mäkelä O, Jalanko H. Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer. Br J Cancer 1986;53:197-202.
111. Paganuzi M, Onetto M, Marroni P, Barone D, Conio M, Aste H, et al. CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases. Cancer 1988;61:2100-8.
112. Tempero MA, Uchida E, Tykasaki H, Burnett DA, Steplewski Z, Pour PM. Relationship of carbo-hydrate antigen 19-9 and Lewis antigen in pancreatic cancer. Cancer Res 1987;40:5501-3.
113. Tian F, Appert HE, Myles J, Howard JM. Prognostic value of serum CA 19-9 levels in pancreatic adenocarcinoma. Ann Surg 1992;215:350-5.
114. von Rosen A, Linder S, Harmenberg U, Pegert S. Serum levels of CA 19-9 and CA 50 in relation to Lewis blood cell status in patients with malignant and benign pancreatic disease. Pancreas 1993;8:160-5.
115. Lindholm L, Holmgren J, Svennerholm L, Fredman P, Nilsson O, Persson B, et al. Monoclonal antibodies against gastrointestinal tumour-associated antigens isolated as monosialogangliosides. Int Arch Allergy Appl Immun 1983;71:178-81.
116. Holmgren J, Lindholm L, Persson B, Lagergård T, Nilsson O, Svennerholm L, et al. Detection by monoclonal antibody of carbohydrate antigen CA-50 in serum of patients with carcinoma. Br Med J 1984;288:1479-82.
117. Bruhn HD, Everding A, Joos B, Hedderich J. Clinical experience with the carbohydrate antigen CA-50 in serum of carcinoma patients. In: Holmgren J, editor. Tumor marker antigens. Lund: Studentlitteratur; 1985. p. 92-103.
118. Chan SH, Lindholm L, Wong L, Oon CJ. Tumor markers in hepatocellular carcinoma in Singaporean Chinese. In: Holmgren J, editor. Tumor marker antigens. Lund: Studentlitteratur; 1985. p. 104-11.
119. Jalanko H, Haglund C, Roberts P, Kuusela P. Tumor markers in gastrointestinal cancers. In: Holmgren J, editor. Tumor marker antigens. Lund: Studentlitteratur; 1985. p. 112-21.
120. Paganuzzi M, Marroni P, Boccardo P, Valenti G, Ferrara GB. Clinical evaluation of CA-50 in sera of patients with different tumors. In: Holmgren J, editor. Tumor marker antigens. Lund: Studentlitteratur; 1985. p. 134-45.
121. Habib NA, Hershman MJ, Smadja C, Wood CB. The use of CA-50 radioimmunoassay inhibition test in the differential diagnosis of benign and malignant liver diseases. Br J Surg 1986;73:758-59.
122. Eskelinen M, Tikanoja S, Collan Y. Clinical evaluation of tumor marker CA 50 in breast cancer diagnostics. Surg Res Commun 1989;6:107-13.
123. Habib NA, Hershman MJ, Haberland F, Papp L, Wood CB, Williamson RCN. The use of CA-50 radioimmunoassay in differentiating benign and malignant pancreatic disease. Br J Cancer 1986;53:697-9.
124. Blind PJ, Dahlgren ST. Serum levels of the carbohydrate antigen CA-50 in pancreatic disease. Acta Chir Scand 1987;153:45-9.
125. Kuusela P, Haglund C, Roberts P, Jalanko H. Comparison of CA-50, a new tumour marker, with CEA and AFP in patients with gastrointestinal diseases. Br J Cancer 1987;55:673-6.
126. Kuusela P, Haglund C, Roberts P. Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and CEA in digestive tract diseases. Br J Cancer 1991;63:636-40.
127. Pasanen P, Eskelinen M, Pikkarainen P, Partanen K, Alhava E, Penttilä I. Clinical evaluation of a new tumour marker CA 242 in pancreatic carcinoma. Br J Cancer 1992;65:731-4.
128. Pasanen P, Eskelinen M, Pikkarainen P, Partanen K, Alhava F., Penttilä I. Clinical value of serum tumour markers CEA, CA 50 and CA 242 in the distinction between malignant versus benign diseases causing jaundice and cholestasis; results from a prospective study. Anticancer Res 1992;12:1689-94.
129. Pålsson B, Masson P, Andren-Sandberg A. The influence of cholestasis on CA-50 and CA 242 in pancreatic cancer and benign biliopancreatic disease. Scand J Gastroenterol 1993;28:981-7.
130. Nilsson O, Mansson JE, Lindholm L, Holmgren J, Svennerholm L. Sialosyllactotetraosylceramide, a novel ganglioside antigen detected in human carcinoma by monoclonal antibody. FEBS Lett 1985;182:398-402.
131. Johansson C, Nilsson O, Bäckström D, Jansson EL, Lindholm L. Novel epitopes on the CA50-carrying antigen: chemical and immunochemical studies. Tumour Biol 1991;12:159-70.
132. Johansson C, Nilsson O, Lindholm L. Comparison of serological expression of different epitopes on the CA50-carrying antigen CanAg. Int J Cancer 1991;48:757-63.
133. Haglund C, Lindgren J, Roberts P, Kuusela P, Nordling S. Tissue expression of the tumour associated antigen CA 242 in benign and malignant pancreatic lesions. A comparison with CA 50 and CA 19-9. Br J Cancer 1989;60:845-51.
134. Nilsson O, Johansson C, Glimelius B, Persson B, Norgaard-Pederson B, Andren-Sandberg A, et al. Sensitivity and specificity of CA 242 in gastrointestinal cancer. A comparison with CEA, CA 50 and CA 19-9. Dr J Cancer 1992;65:215-21.
135. Röthlin MA, Joller H, Largiader F. CA 242 is a new tumor marker for pancreatic cancer. Cancer 1993;71:701-7.
136. Kawa S, Tokoo M, Hasebe O, Hayashi K, Imai H, Oguchi H, et al. Comparative study of CA 242 and CA 19-9 for the diagnosis of pancreatic cancer. Br J Cancer 1994;70:481-6.
137. Banfi G, Bravi S, Ardemagni A, Zerbi A. CA 19.9, CA 242 and CEA in the diagnosis and follow-up of pancreatic cancer. Int J Bid Markers 1996;11:77-81.
138. Pasanen P, Eskelinen M, Pikkarainen P, Partanen K, Alhava E, Penttilä I. ROC curve analysis of the tumour markers CEA, CA 50 and CA 242 in pancreatic cancer, results from a prospective study. Br J Cancer 1993;67:852-5.
139. Pasanen P, Eskelinen M, Partanen K, Pikkarainen P, Penttilä I, Alhava E. Multivariate analysis of six serum tumour markers (CEA, CA 50, CA 242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancy. Anticancer Res 1995;15:2731-8.
140. Gupta MK, Arciaga R, Bukowski R, Gaur P. CA-195: a new sensitive monoclonal antibody-defined tumor marker for pancreatic cancer. J Tumor Marker Oncol 1987;2;201-6.
141. Fukuta S, Magnani JL, Gaur PK, Ginsburg V. Monoclonal antibody CC3C195, which detects cancer-associated antigens in serum, binds to the human Lewis(a) blood group antigen and to its sialylated derivative. Arch Biochem Biophys 1987;255:214-6.
142. Bhargava AK, Petrelli NJ, Karna A, Parshall PL, Fitzpatrick JE, Douglass HO, et al. Serum levels of cancer-associated antigen CA-195 in gastrointestinal cancers and its comparison with CA 19-9. J Clin Lab Anal 1989;3:370-7.
143. Taylor OM, Cooper EH, Benson EA, McMahon MJ. The prognostic value of the tumour markers CA 195 and CEA in patients with adenocarcinoma of the pancreas. Eur J Surg Oncol 1992;18:508-13.
144. Andicoechea A, Vizosu F, Alexandre E, Martinez A, Diez M, Riera L, et al. Comparative study of carbohydrate antigen 195 and carcinoembryonic antigen for the diagnosis of pancreatic carcinoma. World J Surg 1999;23:227-32.
145. Bast RC, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981;68:1331-7.
146. Bast RC, Klug TN, St John E, Jenison E, Niloff JM, Lazarus H, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309:883-7.
147. Ruihal A, Encabo G, Martinez-Miralles E, Murcia C, Capdevila JA, Salgado A, et al. CA 125 sera levels in nonmalignant pathologies. Bull Cancer 1984;71:145-8.
148. Haglund C. Tumour marker antigen CA 125 in pancreatic cancer: a comparison with CA 19-9 and CFA. Br J Cancer 1986;54:897-901.
149. Bosslet K, Kern HF, Kanzy EJ, Steinstraesser A, Schwarz A, Lüben G, et al. A monoclonal antibody with binding and inhibitory activity on human pancreatic carcinoma cells. Cancer Immunol Immunother 1986;23:185-91.
150. Buchler M, Friess H, Malfertheiner P, Schuttheiss KH, Muhrer KM, Beger HG, et al. Studies of pancreatic cancer utilizing monoclonal antibodies. Int J Pancreatol 1990;7:151-7.
151. Friess H, Buchler M, Auerbach B, Weber A, Malfertheiner P, Hammer K, et al. CA 494 - a new tumor marker for the diagnosis of pancreatic cancer. Int J Cancer 1993;53:759-63.
152. Parker N, Makin CA, Ching CK, Eccleston D, Tuylor OM, Milton JD, et al. A new enzyme-linked lectin/mucin antibody sandwich assay (CAM 17.1/WGA) assessed in combination with CA 19-9 and peanut lectin binding assay for the diagnosis of pancreatic cancer. Cancer 1992;70:1062-8.
153. Makin CA, Bobrow LG, Bodmer WF. Monoclonal antibody to cytokeratin for use in routine histopathology. J Clin Pathol 1984;37:975-83.
154. Raouf A, Parker N, Iddon D, Ryder S, Langdon-Brown B, Milton JD. Ion-exchange chromatography of purified colonic mucus glycoproteins in inflammatory bowel disease: absence of a selective subclass defect. Gut 1991;32:1139-46.
155. Gansauge F, Gansauge S, Parker N, Beger MI, Poch B, Link KH, et al. CAM 17.1 - a new diagnostic marker in pancreatic cancer. Br J Cancer 1996;74:1997-2002.
156. Yiannakou JY, Newland P, Calder F, Kingsnorth AN, Rhodes JM. Prospective study of CAM 17.1/WGA mucin assay for serological diagnosis of pancreatic cancer. Lancet 1997;349:389-92.
157. Almoguerra C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988;53:549-54.
158. Eskelinen M, Haglund U. Prognosis of human pancreatic adenocarcinoma: review of clinical and histopathological variables and possible uses of new molecular methods. Fur J Surg. In press 1999.
159. Harris CC. At the crossroads of molecular carcinogenesis and risk assessment. Science 1993;262:1980-1.
160. Crawford LV, Pim DC, Bulbrook RD. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 1992;30:403-8.
161. Schlichtholz. B, Tredaniel J, Lubin R, Zaleman G, Hirsch A, Soussi T. Analysis of p53 antibodies in sera from patients with lung carcinoma define immunodominant regions in the p53 protein. Br J Cancer 1994;69:809-16.
162. Raedle J, Oremek G, Welker M, Roth WK, Caspary WF, Zeuzem S. p53 autoantibodies in patients with pancreatitis and pancreatic carcinoma. Pancreas 1996;13:241-6.
163. Malchow-Møller A, Matzen P, Bjerregaard B, Hilden J, Holst-Christensen J, Stæhr Johansen T, et al. Causes and characteristics of 500 consecutive cases of jaundice. Scand J Gastroenterol 1981;16:1-6.
164. Lindberg G Studies on diagnostic decision making in jaundice [dissertation]. Stockholm: Karolinska Institutet; 1982.
165. Kalser MH, Barkin JS, Redhammer D, Heal A. Circulating carcinoembryonic antigen in pancreatic carcinoma. Cancer 1978;42:1468-71.
166. Engarås B, Hafström LO, Kewenter J, Nilsson O, Wedel H. Standard serum concentrations and normal fluctuations of CEA, CA 50 and CA 242 during twelve months in men and women aged 60-64 years without malignant disease. Eur J Surg 1999;165:110-6.